Updated efficacy and safety results from phase III GLOW study evaluating zolbetuximab plus CAPOX as first-line (1L) treatment for patients with claudin-18 isoform 2-positive (CLDN18.2+), HER2L, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma

Lordick F., Shah M. A., Shitara K., Ajani J. A., Bang Y., Enzinger P. C., ...Daha Fazla

ANNALS OF ONCOLOGY, 2023 (SCI-Expanded, Scopus) identifier

  • Yayın Türü: Makale / Özet
  • Basım Tarihi: 2023
  • Doi Numarası: 10.1016/j.annonc.2023.10.270
  • Dergi Adı: ANNALS OF ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, CAB Abstracts, EMBASE, MEDLINE
  • Bezmiâlem Vakıf Üniversitesi Adresli: Evet